Detalhe da pesquisa
1.
Lung Cancer: A Wily Genetic Opponent.
Cell
; 169(5): 777-779, 2017 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28525750
2.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Nature
; 620(7973): 393-401, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407818
3.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med
; 383(21): 2018-2029, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207094
4.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306090
5.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Future Oncol
; 17(34): 4649-4656, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34585621
6.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 271-282, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838007
7.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838015
8.
Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer.
Cancer
; 126(20): 4473-4484, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757294
9.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(9): 829-838, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28586279
10.
Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
AJR Am J Roentgenol
; 214(4): 766-774, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31887093
11.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 20(12): 1691-1701, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669155
12.
Clinical Management of Adverse Events Associated with Lorlatinib.
Oncologist
; 24(8): 1103-1110, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890623
13.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
N Engl J Med
; 374(1): 54-61, 2016 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26698910
14.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413378
15.
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Br J Cancer
; 118(1): 38-42, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29149104
16.
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Proc Natl Acad Sci U S A
; 112(5): 1547-52, 2015 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605928
17.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 18(7): 874-886, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28602779
18.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol
; 18(12): 1590-1599, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074098
19.
Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med
; 370(13): 1189-97, 2014 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24670165
20.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med
; 371(21): 1963-71, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25264305